Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 332,500 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 332,500 shares of the company’s stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $89.11, for a total transaction of $29,629,075.00. Following the completion of the sale, the chief executive officer owned 9,074,532 shares of the company’s stock, valued at $808,631,546.52. This represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Tempus AI Trading Down 2.9%

Shares of NASDAQ:TEM opened at $86.27 on Friday. The stock has a market capitalization of $14.99 billion, a PE ratio of -72.50 and a beta of 4.87. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $104.32. The firm has a fifty day moving average price of $85.24 and a 200 day moving average price of $69.15. The company has a current ratio of 1.54, a quick ratio of 1.43 and a debt-to-equity ratio of 2.58.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $314.64 million during the quarter, compared to the consensus estimate of $296.84 million. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The firm’s revenue was up 89.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. Analysts expect that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research report on Wednesday, October 8th. Cowen downgraded shares of Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Canaccord Genuity Group assumed coverage on shares of Tempus AI in a report on Monday, October 20th. They set a “buy” rating and a $110.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $70.00 price target on shares of Tempus AI in a report on Friday, August 8th. Finally, Morgan Stanley upped their price target on shares of Tempus AI from $65.00 to $68.00 and gave the company an “overweight” rating in a report on Tuesday, August 12th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Tempus AI currently has a consensus rating of “Hold” and an average target price of $79.38.

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently made changes to their positions in TEM. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Tempus AI in the first quarter valued at about $440,000. Janney Montgomery Scott LLC bought a new stake in shares of Tempus AI in the 1st quarter worth approximately $416,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Tempus AI in the 1st quarter worth approximately $1,019,000. Spire Wealth Management bought a new stake in shares of Tempus AI in the 1st quarter worth approximately $69,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Tempus AI by 10.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,594 shares of the company’s stock worth $268,000 after acquiring an additional 515 shares during the period. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.